Breast cancer continues to be a significant global health concern, affecting millions of individuals and their families worldwide. According to recent statistics from the World Health Organization (WHO), breast cancer remains one of the most prevalent forms of cancer among women, accounting for a substantial number of new cancer cases each year. Amid this daunting reality, advancements in medical research and innovative therapy approaches offer hope for improved outcomes and enhanced quality of life for breast cancer patients. One such promising development is the application of Dendritic Cell Therapy, which has shown encouraging results in the management and therapy of breast cancer patients. In this article, we will explore the prevailing breast cancer statistics at Immucura, shed light on the scope of this disease, and also delve into the latest findings regarding the efficacy of Dendritic Cell Therapy in the cure of breast cancer.
At Immucura, a comprehensive analysis of cancer statistics and survival rates of 409 patients, was carried out from December 2020 to April 2023. It reveals valuable insights into the prevalence and outcomes of different cancer types. With a focus on breast cancer, this article includes cancer grades, explores the presence of metastases, and presents encouraging survival rates over 1, 3, 5, and 10 years for all cancers combined and specifically for breast cancer cases.
An examination of Immucura’s patient data (total number=409) during that specified period of time shows a nearly equal distribution between sexes, with 49.6% male and 50.4% female patients. Among the 24 cancer types recorded, a sample of 117 of the patients was selected for a study. The findings indicated that breast cancer represented a significant proportion, accounting for 22.2% of cases. Other prevalent cancer types include the brain and central nervous system (12.8%), colorectal (11.1%), pancreas (10.3%), and prostate (7.7%). Collectively, these findings emphasize the importance of addressing breast cancer due to its relatively high incidence.
When assessing cancer grades, Immucura’s data indicates varying levels of malignancy. Notably, a significant proportion, 77.8%, falls under grade 4, highlighting the fact that many patients wait very long before starting complementary therapies like DCT. Only 1.7% of the cases are grade 1, while grades 2 and 3 represent 4.3% and 6.0%, respectively. Regarding metastases, approximately 79.4% of patients presented with metastatic cancer, underscoring the need for effective cancer therapy targeting advanced-stage diseases.
Examining survival rates provides crucial insights into the effectiveness of the therapy. After 1 year, Immucura’s data reveals a promising 78% survival rate among all cancers combined, based on 109 patients. However, survival rates decline over time, with 44.2% at 3 years (86 patients), 31.6% at 5 years (79 patients), and 9.2% at 10 years (76 patients).
For patients diagnosed with grade 4 cancers, the survival rates at Immucura provide a more specific perspective. Within the first year, the survival rate stood at 76.7% among 86 patients. Over 3 years, the rate decreases to 41.4% (70 patients) and further drops to 29.2% at 5 years (65 patients). Alas, the 10-year survival rate for grade 4 cancers is notably lower, at 6.3% (63 patients). These findings highlight the challenges associated with managing advanced-stage cancers and the importance of early detection and intervention.
From the sample of 117 patients, 26 patients were diagnosed with breast cancer. Analyzing breast cancer cases specifically, Immucura’s data showcases the distribution of cancer grades and the occurrence of metastases. Among breast cancer patients, grade 4 cancers account for a significant 69.2%, indicating the severity of advanced breast cancer cases. Furthermore, 73.1% of patients presented with metastatic breast cancer.
Considering the survival rates for breast cancer, Immucura’s data is promising. Over the course of a year, all 23 patients diagnosed with breast cancer survived, showcasing a 100% survival rate. At 3 years, the rate remains high at 87.5% (16 patients), followed by 78.6% at 5 years (14 patients). However, the 10-year survival rate decreases to 25% (12 patients), underscoring the ongoing challenges associated with long-term survival for breast cancer patients.
At Immucura, a comprehensive analysis of cancer statistics and survival rates was conducted on 409 patients from December 2020 to April 2023. Among the different cancer types, breast cancer accounted for a significant proportion, representing 22.2% of cases. The analysis considered cancer grades and the presence of metastases. Grade 4 cancers, indicating advanced and severe cases, constituted a significant proportion, with 77.8% falling into this category. Additionally, approximately 79.4% of patients presented with metastatic cancer. Analyzing breast cancer cases specifically, Immucura’s data revealed that grade 4 cancers accounted for a significant proportion (69.2%) among breast cancer patients. Moreover, 73.1% of breast cancer patients presented with metastatic breast cancer.
In terms of survival rates for breast cancer, Immucura‘s data showed promising outcomes. All 23 patients diagnosed with breast cancer survived over the course of one year, indicating a 100% survival rate. At 3 years, the rate remained high at 87.5%, followed by 78.6% at 5 years. However, the 10-year survival rate decreased to 25%, highlighting the ongoing challenges associated with long-term survival for breast cancer patients.